Development of Triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations

被引：0
|
作者：
Chou, Chih-Chien
Kardos, Jordan
Yang, Becky
Orf, Jessica
Dave, Rutwij
Lai, Yurong
Lee, Chingwei V.
Papalia, Giuseppe A.
Boyd, Kelli
Diehl, Lauri
Scholler, Nathalie
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-07-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-07-12
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
    Seligson, John M.
    Patron, Alexandra M.
    Berger, Michael J.
    Harvey, R. Donald
    Seligson, Nathan D.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (07) : 921 - 931
  • [22] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Isakoff, S. J.
    Abramson, V.
    Starodub, A. N.
    O'Shaughnessy, J.
    Kalinsky, K.
    Moroose, R.
    Shah, N.
    Juric, D.
    Shapiro, G. I.
    Guarino, M.
    Ocean, A. J.
    Messersmith, W. A.
    Berlin, J. D.
    Wegener, W. A.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2017, 77
  • [23] Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer
    Li, Lan
    Cao, Jiawei
    Chen, Chunyan
    Qin, Yaqian
    He, Licai
    Gu, Haihua
    Wu, Guang
    HELIYON, 2023, 9 (04)
  • [24] Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
    Okajima, Daisuke
    Yasuda, Satoru
    Maejima, Takanori
    Karibe, Tsuyoshi
    Sakurai, Ken
    Aida, Tetsuo
    Toki, Tadashi
    Yamaguchi, Junko
    Kitamura, Michiko
    Kamei, Reiko
    Fujitani, Tomomichi
    Honda, Tomoyo
    Shibutani, Tomoko
    Muramatsu, Sumie
    Nakada, Takashi
    Goto, Riki
    Takahashi, Shu
    Yamaguchi, Miki
    Hamada, Hirofumi
    Noguchi, Yutaka
    Murakami, Masato
    Abe, Yuki
    Agatsuma, Toshinori
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12) : 2329 - 2340
  • [25] TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?
    Perol, Maurice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24)
  • [26] Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer
    Schipilliti, Francesca Matilde
    Drittone, Denise
    Mazzuca, Federica
    La Forgia, Daniele
    Guven, Deniz Can
    Rizzo, Alessandro
    HELIYON, 2024, 10 (07)
  • [27] Development of CDCP1-targeting antibody-drug conjugate for Triple negative and metastatic breast cancer
    Gough, Madeline
    Khan, Tashbib
    Kwah, Kayden
    He, Yaowu
    Ratnayake, Gishan
    Pyke, Christopher
    Snell, Cameron
    Hooper, John
    Kryza, Thomas
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Correlation of Trop-2 expression with clinicopathological characteristics and outcome in triple-negative breast cancer (TNBC)
    Izci, Hava
    Punie, Kevin
    Waumans, Lise
    Laenen, Annouschka
    Wildiers, Hans
    Verdoodt, Freija
    Desmedt, Christine
    Ardui, Jan
    Smeets, Ann
    Han, Sileny
    Nevelsteen, Ines
    Neven, Patrick
    Floris, Giuseppe
    CANCER RESEARCH, 2022, 82 (04)
  • [29] Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon
    Khadela, Avinash
    Soni, Shruti
    Shah, Aayushi C.
    Pandya, Aanshi J.
    Megha, Kaivalya
    Kothari, Nirjari
    Avinash, C. B.
    MEDICAL ONCOLOGY, 2022, 40 (01)
  • [30] RON Receptor-Targeted Antibody-Drug Conjugate Therapy Ablates Cancer Stem Cells and Induces Long-term Tumor Regressions in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
    Suthe, Sreedhar Reddy
    Yao, Hang-Ping
    Wang, Ming-Hai
    FASEB JOURNAL, 2019, 33
12345